ACLA Statement on FDA’s Revised Policy for Serologic Tests
WASHINGTON, D.C. – Following the revised policy on serologic testing announced today by the Food and Drug Administration, ACLA President Julie Khani issued the following statement:
“ACLA is reviewing the latest announcement by the FDA. We commend the agency for its continued diligence in evaluating the available data regarding testing options and implementing policies that promote the public’s health. It is essential that patients and clinicians can depend on the accuracy and reliability of COVID-19 tests, and we look forward to continuing to work with the administration to expand the availability of high-quality tests nationwide.”
To read ACLA’s recent white paper, Supporting a Comprehensive, Nationwide Response to COVID-19: The Role of Serologic Testing, click here.
# # #
ACLA is a not-for-profit association representing the nation’s leading clinical and anatomic pathology laboratories, including national, regional, specialty, hospital, ESRD and nursing home laboratories. The clinical laboratory industry employs nearly 295,000 people directly, and generates over 117,000 additional jobs in supplier industries. Clinical laboratories are at the forefront of personalized medicine, driving diagnostic innovation and contributing more than $106 billion to the nation’s economy.